Effect of temperature, medium composition, and cell passage on production of herpes-based viral vectors

Biotechnology and Bioengineering

Volumn 79, Issue 1, 2002, Pages 112-119

  Wechuck, James B ^a   Ozuer, Ali ^a   Goins, William F ^b   Wolfe, Darren ^b   Oligino, Thomas ^b   Glorioso, Joseph C ^b   Ataai, Mohammad M ^a  

^a University of Pittsburgh   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Gene therapy; Half life; HSV 1; Passage effect; Viral vectors

Indexed keywords

BIOTECHNOLOGY; NEUROLOGY; TISSUE; VECTORS; VIRUSES;

CELL PASSAGE;

GENES;

GLUCOSE; LACTIC ACID; VIRUS VECTOR;

ARTICLE; CELL GROWTH; CELL METABOLISM; CENTRAL NERVOUS SYSTEM; CULTURE MEDIUM; GENE TRANSFER; HALF LIFE TIME; HERPES SIMPLEX VIRUS 1; INCUBATION TIME; NONHUMAN; REPRODUCIBILITY; TEMPERATURE; THERMOSTABILITY; VIRUS TITRATION;

ANIMALS; CELL CULTURE TECHNIQUES; CELL PROLIFERATION; CELL SURVIVAL; CERCOPITHECUS AETHIOPS; GENETIC VECTORS; HERPESVIRUS 1, HUMAN; TEMPERATURE; VERO CELLS; VIRUS CULTIVATION;

HUMAN HERPESVIRUS 1; SIMPLEXVIRUS;

EID: 0037025217     PISSN: 00063592     EISSN: None     Source Type: Journal    
DOI: 10.1002/bit.10310     Document Type: Article

References (45)

1. Herpes simplex virus vector-mediated dystrophin gene transfer and expression in MDX mouse skeletal muscle
2. Gene therapy scores against cancer
3. Sustained high-level expression of full-length human factor VIII and restoration of clotting activity in hemophilic mice using a minimal adenovirus vector
4. Gene therapy of human severe combined immunodeficiency (SCID)-XI disease
5. Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma
6. Isolation and characterization of deletion mutants of Herpes simplex virus type 1 in the gene encoding immediate-early regulatory protein ICP4
7. A novel herpes vector for the high-efficiency transduction of normal and malignant human hematopoietic cells
8. Effects of long-term passaging of BTI-TnSB1-4 insect cells on growth and recombinant protein production
9. Studies of defective herpes simplex viruses
10. Antinociceptive effect of a genomic herpes simplex virus-based vector expressing human proenkephalin in rat dorsal root ganglion
11. Kinetic analyses of stability of simple and complex retroviral vectors
12. Improved cell survival by the reduction of immediate-early gene expression in replication-defective mutants of herpes simplex virus type I but not by mutation of the viron host shutoff function
13. Optimized conditions for the production of recombinant amphotropic retroviral vector preparations
14. Viral vectors for gene therapy: The art of turning infectious agents into vehicles of therapeutics
15. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector
16. Combination gene therapy using multiple immunomodulatory genes transferred by a defective infectious single-cycle herpes virus in squamous cell cancer
17. Improved methods of retroviral vector transduction and production for gene therapy
18. Development of herpes simplex virus replication defective multigene vectors for combination gene therapy applications
19. Deletion of multiple immediate-early genes from herpes simplex virus reduces cytotoxicity and permits long term gene expression in neurons
20. Effect of pH on the kinetics of herpes simplex virus inactivation at 36 degrees
21. Influence of environmental pH on the preservation and inactivation of herpes simplex virus
22. Physical integrity of herpes simplex virus following thermal inactivation
23. Thermal-pH inactivation of herpes simplex virus: Interdependence of the medium composition and the pH on the rate of virus inactivation. Brief report
24. Optimization of environmental factors for the production and handling of recombinant retrovirus
25. Herpes simplex virus type 1 deletion variants 1714 and 1716 pinpoint neurovirulenece-related sequences in Glasgow strain 17+ between immediate early gene 1 and the 'a' sequence
26. Replication-defective HSV vectors for gene transfer in vivo
27. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: Results of a phase I trial
28. Experimental therapy of human glioma by means of a genetically engineered virus mutant
29. Interference of the low-pH inactivated herpes simplex virus type 1 (HSV-1) strain HSZP with the early shutoff function of superinfecting HSV-1 strain KOS
30. The primary production of an infectious recombinant Herpes Simplex Virus vaccine
31. Effect of genetic background and culture conditions on the production of herpes virus-based gene therapy vectors
32. Therapeutic levels of human factor VIII and IX using HIV-1-based lentiviral vectors in mouse liver
33. Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma
34. Angiogenesis gene therapy: Phase I assessment of direct intramyocardial administration of an adeno-virus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease
35. Functional interaction between herpes simplex virus immediate-early proteins during infection: Gene expression as a consequence of ICP27 and different domains of ICP4
36. The herpes simplex virus immediate-early protein ICP0 affects transcription from the viral genome and infected-cell survival in the absence of ICP4 and ICP27
37. Persistence and expression of the herpes simplex virus genome in the absence of immediate-early proteins
38. Gene therapy: Trials and tribulations
39. Safety and biological efficacy of an adeno-associated virus vector-cystic fibrosis transmembrane regulator (AAV-CFTR) in the cystic fibrosis maxillary sinus
40. Thermostabilization and thermosensitization of herpesvirus
41. Effect of protease inhibitors on yield of HSV-1-based viral vectors
42. 1 34.5 deletion mutants in rodent models
43. Systemic delivery of nerve growth factor following herpesvirus gene transfer
44. Prolonged gene expression and cell survival after infection by a herpes simplex virus mutant defective in the immediate-early genes encoding ICP4, ICP27, and ICP22
45. Irreversible conversion of the physical state of herpes simplex virus preceding inactivation by thermal or antibody treatment